
Evolent Health (EVH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
483.6M
Gross Profit
102.5M
21.19%
Operating Income
4.0K
0.00%
Net Income
-64.6M
-13.36%
EPS (Diluted)
$-0.63
Balance Sheet Metrics
Total Assets
2.7B
Total Liabilities
1.7B
Shareholders Equity
935.5M
Debt to Equity
1.84
Cash Flow Metrics
Operating Cash Flow
-23.4M
Free Cash Flow
-4.0M
Revenue & Profitability Trend
Evolent Health Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 2.6B | 2.0B | 1.4B | 908.0M | 924.6M |
Cost of Goods Sold | 2.2B | 1.5B | 1.0B | 657.6M | 696.6M |
Gross Profit | 367.4M | 460.5M | 316.6M | 250.4M | 228.1M |
Gross Margin % | 14.4% | 23.4% | 23.4% | 27.6% | 24.7% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 263.0M | 358.1M | 269.3M | 219.5M | 210.4M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 263.0M | 358.1M | 269.3M | 219.5M | 210.4M |
Operating Income | -14.1M | -21.1M | -19.9M | -29.1M | -43.2M |
Operating Margin % | -0.6% | -1.1% | -1.5% | -3.2% | -4.7% |
Non-Operating Items | |||||
Interest Income | 5.5M | 5.3M | 1.4M | 407.0K | 2.6M |
Interest Expense | 24.7M | 54.2M | 15.6M | 25.4M | 28.3M |
Other Non-Operating Income | -29.8M | -132.4M | -28.0M | 24.3M | -261.7M |
Pre-tax Income | -63.0M | -202.4M | -62.1M | -29.8M | -330.5M |
Income Tax | -1.4M | -89.4M | -43.4M | 483.0K | -2.4M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -61.6M | -113.0M | -19.2M | -37.6M | -334.2M |
Net Margin % | -2.4% | -5.8% | -1.4% | -4.1% | -36.1% |
Key Metrics | |||||
EBITDA | 106.5M | 46.4M | 7.4M | 90.3M | 30.8M |
EPS (Basic) | $-0.81 | $-1.28 | $-0.20 | $-0.44 | $-3.94 |
EPS (Diluted) | $-0.81 | $-1.28 | $-0.20 | $-0.44 | $-3.94 |
Basic Shares Outstanding | 114682000 | 111251000 | 93699000 | 86067000 | 84928000 |
Diluted Shares Outstanding | 114682000 | 111251000 | 93699000 | 86067000 | 84928000 |
Income Statement Trend
Evolent Health Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 104.2M | 192.8M | 188.2M | 266.3M | 319.0M |
Short-term Investments | - | - | - | - | 3.9M |
Accounts Receivable | 414.7M | 446.7M | 254.7M | 130.6M | 124.1M |
Inventory | - | - | - | - | - |
Other Current Assets | 28.9M | 30.3M | 20.7M | 51.4M | - |
Total Current Assets | 607.1M | 683.7M | 478.1M | 524.0M | 547.6M |
Non-Current Assets | |||||
Property, Plant & Equipment | 6.1M | 12.0M | 49.0M | 50.2M | 57.8M |
Goodwill | 3.0B | 3.0B | 1.9B | 1.1B | 963.0M |
Intangible Assets | 680.2M | 752.0M | 442.8M | 279.8M | 265.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 31.9M | 33.0M | 32.3M | 52.4M | 53.7M |
Total Non-Current Assets | 1.9B | 2.0B | 1.3B | 895.5M | 824.1M |
Total Assets | 2.5B | 2.7B | 1.8B | 1.4B | 1.4B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 96.0M | 48.2M | 57.2M | 96.1M | 32.0M |
Short-term Debt | 198.2M | 9.7M | 7.1M | 7.1M | 33.9M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | 28.0M |
Total Current Liabilities | 715.5M | 674.2M | 433.4M | 445.5M | 403.3M |
Non-Current Liabilities | |||||
Long-term Debt | 515.5M | 635.1M | 469.0M | 273.4M | 325.9M |
Deferred Tax Liabilities | 119.0M | 121.2M | 50.7M | 1.4M | 679.0K |
Other Non-Current Liabilities | 3.0M | 3.6M | 4.7M | 5.5M | 22.1M |
Total Non-Current Liabilities | 827.7M | 938.4M | 524.4M | 280.3M | 348.8M |
Total Liabilities | 1.5B | 1.6B | 957.9M | 725.8M | 752.1M |
Equity | |||||
Common Stock | 1.2M | 1.2M | 1.0M | 908.0K | 859.0K |
Retained Earnings | -780.8M | -719.2M | -606.2M | -626.8M | -589.2M |
Treasury Stock | 21.1M | 21.1M | 21.1M | 21.1M | 21.1M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.0B | 1.1B | 859.4M | 693.6M | 619.6M |
Key Metrics | |||||
Total Debt | 713.7M | 644.8M | 476.1M | 280.5M | 359.8M |
Working Capital | -108.4M | 9.4M | 44.6M | 78.5M | 144.4M |
Balance Sheet Composition
Evolent Health Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -61.6M | -113.0M | -19.2M | -37.6M | -334.2M |
Depreciation & Amortization | 118.4M | 123.4M | 67.2M | 60.0M | 61.5M |
Stock-Based Compensation | 39.7M | 40.5M | 34.0M | 16.7M | 14.6M |
Working Capital Changes | -74.2M | 10.9M | -77.8M | -22.5M | -71.5M |
Operating Cash Flow | 55.1M | 79.7M | 12.0M | 30.6M | -289.3M |
Investing Activities | |||||
Capital Expenditures | - | - | -38.4M | -25.0M | -29.5M |
Acquisitions | -7.3M | 870.0K | 5.6M | 14.2M | 0 |
Investment Purchases | - | 0 | 0 | -3.0M | -11.2M |
Investment Sales | - | 0 | 0 | 500.0K | 143.4M |
Investing Cash Flow | -38.0M | -386.8M | -259.1M | -15.8M | 261.1M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -20.1M | -18.8M | -14.9M | -1.3M | -20.0M |
Debt Issuance | 58.6M | 647.5M | 219.7M | 0 | 30.1M |
Debt Repayment | 0 | -464.2M | 0 | -98.8M | -16.6M |
Financing Cash Flow | -4.0M | 268.8M | 127.1M | -42.8M | -14.4M |
Free Cash Flow | -6.1M | 113.8M | -49.9M | 13.8M | -45.7M |
Net Change in Cash | 13.0M | -38.3M | -120.0M | -28.0M | -42.7M |
Cash Flow Trend
Evolent Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-11.11
Forward P/E
6.29
Price to Book
1.16
Price to Sales
0.48
PEG Ratio
-0.02
Profitability Ratios
Profit Margin
-5.94%
Operating Margin
0.64%
Return on Equity
-11.04%
Return on Assets
-0.21%
Financial Health
Current Ratio
1.01
Debt to Equity
75.85
Beta
0.82
Per Share Data
EPS (TTM)
$-1.60
Book Value per Share
$7.73
Revenue per Share
$19.05
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
evh | 1.0B | -11.11 | 1.16 | -11.04% | -5.94% | 75.85 |
Veeva Systems | 46.5B | 60.37 | 7.46 | 14.06% | 27.34% | 1.24 |
Ge Healthcare | 33.5B | 15.03 | 3.45 | 25.80% | 11.22% | 107.67 |
Certara | 1.8B | 223.60 | 1.68 | 0.75% | 1.97% | 29.00 |
10x Genomics | 1.7B | -8.79 | 2.17 | -11.30% | -13.13% | 11.22 |
GoodRx Holdings | 1.6B | 51.89 | 2.53 | 5.27% | 4.33% | 85.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.